nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

14.03.2018 | Original Article

Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1

verfasst von: Peng Yin, Guizhen Song, Zhenhua Jiang

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytotoxic platinum-based drug used for chemotherapy of different types of human cancers such as NPC. Nevertheless, the effects of CIS on the migration and invasion of human NPC cells and the underlying molecular mechanisms have not yet been fully scrutinized.

Methods

In this work, we tested the effect of CIS on the proliferation, migration and invasion of NPC cells. The results exhibited that this drug exerts remarkable inhibitory effects on the proliferation, migration and invasion of NPC cells in a dose-dependent manner. Western blotting and real time RT-PCR were used for expression analyses.

Results

We found that CIS treatment led to a dose-dependent inhibition of Endothelin-1 (ET1) expression, at protein as well as mRNA levels in NPC cells. CIS was also found to activate the expression of BTG1 in NPC cells. Moreover, mechanistic analyses revealed that CIS increased the expression of B cell translocation gene 1 (BTG1) to suppress the expression of ET1. Furthermore, we show that ET1 could not be induced in CIS-resistant cells with suppressed BTG1 expression, and subsequently demote the proliferation, migration and invasion of NPC cells.

Conclusions

These findings provided compelling evidence of the role of CIS in suppressing NPC metastasis and its underlying molecular mechanisms.

Cui Q, Feng FT, Xu M, Liu WS, Yao YY, Xie SH, Li XZ, Ye ZL, Feng QS, Chen LZ, Bei JX, Feng L, Huang QH, Jia WH, Cao SM, Chang ET, Ye W, Adami HO, Zeng YX (2016) Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein–Barr virus genetic variants. Oncotarget. https://doi.org/10.18632/oncotarget.11144

Jin GQ, Yang J, Liu LD, Su DK, Wang DP, Zhao SF, Liao ZL (2016) The diagnostic value of 1.5-T diffusion-weighted MR imaging in detecting 5–10 mm metastatic cervical lymph nodes of nasopharyngeal carcinoma. Medicine 95(32):e4286. https://doi.org/10.1097/md.0000000000004286 CrossRefPubMedPubMedCentral

Lu L, Li J, Zhao C, Xue W, Han F, Tao T, Chang H, Jia W, Lu T (2016) Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma. Oral Oncol 60:18–24. https://doi.org/10.1016/j.oraloncology.2016.06.013 CrossRefPubMed

Maingon P, Blanchard P, Bidault F, Calmels L (2016) Radiotherapy for nasopharyngeal carcinoma. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique. https://doi.org/10.1016/j.canrad.2016.07.031

Yao K, Yang S, Shen J, Zhang R, Li L (2016) HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc (EUFOS) Affil German Soc Oto-Rhino-Laryngol Head Neck Surg. https://doi.org/10.1007/s00405-016-4264-2

Li JG, Venigalla P, Leeman JE, LaPlant Q, Setton J, Sherman E, Tsai J, McBride S, Riaz N, Lee N (2016) Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. Laryngoscope. https://doi.org/10.1002/lary.26139

Wang Y, Wang ZQ, Jiang YX, Wang FH, Luo HY, Liang Y, Wang DS, Li YH (2016) A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. Expert Opin Pharmacother 17(12):1585–1590. https://doi.org/10.1080/14656566.2016.1204293 CrossRefPubMed

Ngan R, Yiu H, Lau W, Yau S, Cheung F, Chan T, Kwok C, Chiu C, Au S, Foo W (2002) Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 13(8):1252–1258CrossRefPubMed

Group INCS., Trial VI (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35(3):463–469CrossRef

10.

Chan AT, Leung S, Ngan RK, Teo PM, Lau W, Kwan W, Hui EP, Yiu H, Yeo W, Cheung F (2005) Overall survival after concurrent cisplatin–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97(7):536–539CrossRefPubMed

11.

Rosanò L, Spinella F, Bagnato A (2013) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13(9):637–651CrossRefPubMed

12.

Lin SX, Zhang Y, Lu J, Liu X, Li XP (2016) Silencing of endothelin-1 suppresses growth, migration, and invasion of nasopharyngeal carcinoma cells in vitro. J Southern Med Univ 36(7):915–920

13.

McKenzie GA, Hinsley EE, Hunter K, Lambert DW (2014) The endothelin axis in head and neck cancer: a promising therapeutic opportunity? J Oral Pathol Med 43(6):395–404CrossRefPubMed

14.

Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY, Hong MH (2006) Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Sci 97(12):1388–1395CrossRefPubMed

15.

Zheng H-c, Li J, Shen D-f, Yang X-f, Zhao S, Wu Y-z, Takano Y, Sun H-z, Su R-J, Luo J-S (2015) BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget 6 (23):19685CrossRefPubMedPubMedCentral

16.

Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ (2006) B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther 5(6):1593–1601CrossRefPubMed

17.

Cho JW, Kim JJ, Park SG, Lee DH, Lee SC, Kim HJ, Park BC, Cho S (2004) Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia. Proteomics 4(11):3456–3463CrossRefPubMed

18.

Sun G, Wang Y, Cheng Y, Hu W (2014) The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Mol Biol Rep 41(9):5979–5988CrossRefPubMed

19.

Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3(1):1351–1371CrossRefPubMedPubMedCentral

20.

Fuertes MA, Alonso C, Pérez JM (2003) Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103(3):645–662CrossRefPubMed

21.

Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Can Res 55(21):5038–5042

22.

Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci 89(7):3070–3074CrossRefPubMedPubMedCentral

23.

Sun X-J, Zhang P, Li H-H, Jiang Z-W, Jiang C-C, Liu H (2013) Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. APJCP 15(9):4019–4023

24.

Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genom 2:34. https://doi.org/10.1186/1755-8794-2-34 CrossRef

25.

Provenzani A, Fronza R, Loreni F, Pascale A, Amadio M, Quattrone A (2006) Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis 27(7):1323–1333. https://doi.org/10.1093/carcin/bgi377 CrossRefPubMed

26.

Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC (2000) Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Investig 106(4):533–539. https://doi.org/10.1172/JCI9476 CrossRefPubMedPubMedCentral

27.

Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST (1999) Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154(2):515–523. https://doi.org/10.1016/S0002-9440(10)65297-2 CrossRefPubMedPubMedCentral

28.

Filali M, Cheng N, Abbott D, Leontiev V, Engelhardt JF (2002) Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J Biol Chem 277(36):33398–33410. https://doi.org/10.1074/jbc.M107977200 CrossRefPubMed

29.

Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF, Waterman ML (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28(1):53–57. https://doi.org/10.1038/88264 PubMed

30.

Jamora C, DasGupta R, Kocieniewski P, Fuchs E (2003) Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 422(6929):317–322. https://doi.org/10.1038/nature01458 CrossRefPubMedPubMedCentral

31.

ten Berge D, Koole W, Fuerer C, Fish M, Eroglu E, Nusse R (2008) Wnt signaling mediates self-organization and axis formation in embryoid bodies. Cell stem cell 3(5):508–518. https://doi.org/10.1016/j.stem.2008.09.013 CrossRefPubMedPubMedCentral

32.

Fan X, Zhou S, Zheng M, Deng X, Yi Y, Huang T (2017) MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother 88:507–514. https://doi.org/10.1016/j.biopha.2017.01.058 CrossRefPubMed

33.

Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W, Zhao L, Li X (2017) A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 41 (3):973–986. https://doi.org/10.1159/000460618

34.

Han X, Zhou Y, You Y, Lu J, Wang L, Hou H, Li J, Chen W, Zhao L, Li X (2017) TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Cell Biol Int. https://doi.org/10.1002/cbin.10734

35.

Hao GJ, Hao HJ, Ding YH, Wen H, Li XF, Wang QR, Zhang BB (2017) Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. FEBS Lett. https://doi.org/10.1002/1873-3468.12566

36.

He M, Chao L, You YP (2016) PRPS1 silencing reverses cisplatin resistance in human breast cancer cells. Biochem Cell Biol. https://doi.org/10.1139/bcb-2016-0106 PubMed

37.

Jiang Y, Wei YQ, Luo F, Zou LQ, Liu JY, Peng F, Huang MJ, He QM (2005) Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study. Cancer Investig 23(2):123–128CrossRef

38.

Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X, Li P, Tao J, Yang H, Wei J, Tang J, Yuan W, Lu Q, Xu X, Gu M (2017) MicroRNA-218 increases the sensitivity of bladder cancer to cisplatin by targeting Glut1. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 41(3):921–932. https://doi.org/10.1159/000460505

39.

Shi L, Yin W, Zhang Z, Shi G (2016) Down-regulation of miR-26b induces cisplatin resistance in nasopharyngeal carcinoma by repressing JAG1. FEBS Open Bio 6(12):1211–1219. https://doi.org/10.1002/2211-5463.12135 CrossRefPubMedPubMedCentral

40.

Sivalingam KS, Paramasivan P, Weng CF, Vijaya Padma V (2017) Neferine potentiates the antitumor effect of cisplatin in human lung adenocarcinoma cells via a mitochondria-mediated apoptosis pathway. J Cell Biochem. https://doi.org/10.1002/jcb.25937 PubMed

41.

Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA (2017) Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.15338

42.

Wu B, Liu ZY, Cui J, Yang XM, Jing L, Zhou Y, Chen ZN, Jiang JL (2017) F-box protein FBXO22 mediates polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int J Mol Sci. https://doi.org/10.3390/ijms18010212

43.

Xiao LY, Kan WM (2017) Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells. Anti-cancer Drugs 28(3):316–321. https://doi.org/10.1097/cad.0000000000000467 CrossRefPubMed

44.

Yu N, Xiong Y, Wang C (2017) Bu-Zhong-Yi-Qi decoction, the water extract of chinese traditional herbal medicine, enhances cisplatin cytotoxicity in A549/DDP cells through induction of apoptosis and autophagy. BioMed Res Int 2017:3692797. https://doi.org/10.1155/2017/3692797 PubMedPubMedCentral

45.

Zhao X, He R, Liu Y, Wu Y, Kang L (2017) UPregulated single-stranded DNA-binding protein 1 induces cell chemoresistance to cisplatin in lung cancer cell lines. Mol Cell Biochem. https://doi.org/10.1007/s11010-017-2970-8

46.

Zhu X, Ji M, Han Y, Guo Y, Zhu W, Gao F, Yang X, Zhang C (2017) PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int J Oncol 50(3):835–846. https://doi.org/10.3892/ijo.2017.3873 CrossRefPubMed

47.

Rosano L, Spinella F, Bagnato A (2013) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13(9):637–651. https://doi.org/10.1038/nrc3546 CrossRefPubMed

48.

Zhao Y, Liao Q, Zhu Y, Long H (2011) Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis. Clin Orthopaed Relat Res 469(11):3190–3199. https://doi.org/10.1007/s11999-011-1939-2 CrossRef

49.

Lee S, Ahn D (2008) Expression of Endothelin-1 and its receptors in cisplatin-induced acute renal failure in mice. Kor J Physiol Pharmacol Off J Kor Physiol Soc Kor Soc Pharmacol 12(4):149–153. https://doi.org/10.4196/kjpp.2008.12.4.149 CrossRef

50.

Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L, Trisciuoglio D, Spinella F, Bagnato A (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61(3):524–532CrossRefPubMed

51.

52.

Sun GG, Wang YD, Cheng YJ, Hu WN (2014) The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Mol Biol Rep 41(9):5979–5988. https://doi.org/10.1007/s11033-014-3475-0 CrossRefPubMed

53.

Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X, Wang E (2013) Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett 336(1):231–239. https://doi.org/10.1016/j.canlet.2013.05.005 CrossRefPubMed

Titel: Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1
verfasst von: Peng Yin
Guizhen Song
Zhenhua Jiang
Publikationsdatum: 14.03.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3536-5

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Bildnachweise

Frau nutzt Gehhilfe /© Photographee.eu / Fotolia (Symbolbild mit Fotomodellen), Darstellung der Dosisverteilung bei Bestrahlung eines Prostatakarzinoms/© Degener, S et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Tablette und Wasserglas in Händen/© fizkes / stock.adobe.com (Symbolbild mit Fotomodell), Ärztin und künstliche Intelligenz sehen sich Befunde an/© Alexander Limbach / Zoonar/picture alliance (Symbolbild mit Fotomodell)

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma

Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids

A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie